Introduction {#Sec1}
============

Coronavirus disease 2019 (COVID-19) is a novel viral disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. The original cases occurred in Wuhan, China, in December 2019 and rapidly spread to other areas worldwide, constituting a pandemic with unimaginable health and economic consequences.

Spain is currently one of the most affected countries, with more than 180,000 reported cases and more than 18,000 deaths; the first case was declared on January 31, 2020. At the present time, approximately 1000 patients aged younger than 19 years have been diagnosed; however, given that asymptomatic or mildly symptomatic children are not tested, the real number is probably much higher.

SARS-CoV-2 infection in children younger than 10 years of age has been described in approximately 1% of identified cases in China \[[@CR1]\]. Although data on children is still limited, most series agree that cases are typically mild, even in infants \[[@CR2], [@CR3]\].

Several reports regarding adults have reported advanced age and underlying pathologies as important risk factors for severe SARS-CoV-2 infection \[[@CR3]\]; however, practically no information is available about the additional risk that chronic comorbidities pose to infected children.

The Spanish Pediatric Nephrology Association links all pediatric nephrologists working in Spain. The objective of this collaborative study is to describe the incidence and characteristics of SARS-CoV-2 infection in Spanish children with chronic renal pathology.

Patients and methods {#Sec2}
====================

A retrospective study was performed (March 1 to April 15, 2020) of children younger than 18 years infected with SARS-CoV-2 previously diagnosed with a chronic renal pathology. For inclusion in the study, SARS-CoV-2 polymerase chain reaction (PCR) result had to be positive. Both inpatients and outpatients were included. An online questionnaire was sent to all the members of the Spanish Pediatric Nephrology Association and was completed by nephrology pediatricians working at 43 hospitals.

Symptoms, analytical and radiological data, syndromic diagnosis, previous underlying disease, immunosuppressive treatment, treatment received for COVID-19 disease, and evolution data were collected.

Results {#Sec3}
=======

From March until April 15, 2020, 16 children (7 girls and 9 boys) with chronic renal pathologies were found by PCR to be positive for SARS-CoV-2. Of these, 6 were patients with ESKD: 3 had undergone renal transplant (1.5, 6, and 10 years ago), and 3 were receiving chronic hemodialysis. Three of the 16 were children with chronic kidney disease (CKD) stages 2--3, and 7 had a normal glomerular filtration rate (GFR). Clinical characteristics are detailed in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and clinical characteristics of patients (*n* total = 16)Patient characteristics*N*/*n* totalSex (σ:φ)(9:7)/16Age  Median age (range)12.32 years (1 month--17 years)  \< 1 year old2/16  1--12 years4/16  \> 12 years10/16CKD stage  Normal GFR7/16  CKD 22/16  CKD 31/16  ESKD    Hemodialysis3/16    Peritoneal dialysis0/16    Transplant3/16Underlying disease  Renal dysplasia5/16  Nephrotic syndrome5/16  Uropathy (megaureter/PUV)2/16  IgA nephropathy1/16  Scarring nephropathy1/16  Vasculitis1/16  Cortical necrosis1/16Exposure to contact8/ 16Signs and symptoms  Fever8/16  Cough6/16  Rhinorrhea6/16  Gastrointestinal symptoms4/16  Asymptomatic3/16Lymphopenia (\< 1500 cells/μl)4/12Abnormal X-ray6/10Respiratory support  None16/16Antiviral treatment6/16  Lopinavir/ritonavir1/16  Hydroxychloroquine6/16  Others0/16Previous immunosuppression9/16  Steroids7/16  Cyclosporin A3/16  Tacrolimus4/16  Mycophenolate3/16  Azathioprine1/16  Everolimus1/16  Levamisol1/16Hospitalization8/16  Days of admission3 [+]{.ul} 0.5 daysICU admissions/deaths0/0Follow-up (median)19 days (32--1)*GFR* glomerular filtration rate, *CKD* chronic kidney disease, *ESKD* end-stage kidney disease, *PUV* posterior urethral valve, *ICU* intensive care unit

A positive contact was present in half of the children. 62.5% of the children had respiratory symptoms (cough and/or rhinorrhea), 50% had fever, and 25% had gastrointestinal symptoms. Three of the children were asymptomatic, and the test was performed because of their contact with a person who tested positive for SARS-CoV-2. Lymphopenia (defined as \< 1500 cells/μl) was present in 4 of 12 patients for whom data were available. X-ray was performed in 10 patients, 6 of which were described as abnormal (4 diffuse infiltrates and 2 focal infiltrates). No patient needed oxygen therapy.

Eight patients were hospitalized, and 8 were managed as outpatients. At admission, 3 patients (2 transplant recipients and 1 with CKD stage 2) were diagnosed with acute kidney injury (AKI) associated with a poor fluid intake; 1 patient had tacrolimus toxicity. All of them returned to basal GFR in a few days.

Of the 16 patients, 9 received chronic immunosuppression: 3 transplant recipients, 1 with vasculitis on chronic hemodialysis, 4 with nephrotic syndromes, and 1 with IgA nephropathy. In the vasculitis case, azathioprine was stopped; in the transplant recipients, mycophenolate was stopped (1 case) or reduced (1 case); and tacrolimus was reduced (1 case) or not modified (1 case). Everolimus was not modified.

Four infected patients were diagnosed with steroid-dependent nephrotic syndrome: 2 were asymptomatic, and maintenance immunosuppression was not modified; in the other 2, coronavirus infection provoked a nephrotic relapse, but prednisone treatment could be administered without complications.

In 6 of the 16 cases, some antiviral treatment was prescribed: 5 patients received only hydroxychloroquine, and 1 first received lopinavir-ritonavir, which was interrupted by gastrointestinal secondary effects, and then hydroxychloroquine.

With a median follow-up of 19 (1--32) days from COVID-19 diagnosis, clinical recovery has been completed in all the patients. No child required admission to the pediatric intensive care unit or died.

Discussion {#Sec4}
==========

Data regarding epidemiological or clinical features of children infected with SARS-CoV-2 are limited; however, it appears that the incidence is much lower than in adults. In the largest pediatric Chinese series published to date, approximately 2% of the 44,672 confirmed cases were children aged 0--19 years \[[@CR4]\]. In Italian data, only 1.2% of the cases reported were children \[[@CR5]\]. In the USA, among 149,086 cases reported for which age was known, 1.7% were among children aged \< 18 years \[[@CR6]\]. In Spain, in official data actualized to April 13, 2020 \[[@CR7]\], only 535 of 113,368 confirmed cases were children \< 15 years (0.47%). This lower incidence probably reflects that only symptomatic patients have been tested in Spain.

Although CKD appears to be associated with enhanced risk of severe COVID-19 disease in adults \[[@CR8]\], little information is available about pediatric patients with CKD. In our study, 16 children with an underlying chronic renal pathology were diagnosed: 3 were asymptomatic, and test was indicated due to their renal pathology and contact with a person who tested positive for SARS-CoV-2. Using as reference the 2 Spanish Pediatric Chronic Kidney Registries that collect data from children with ESKD (dialysis or transplant) and from children with predialysis CKD (stages 2--5), we can estimate an incidence of 0.61% for children with ESKD and 0.35% for predialysis stages, similar to that of the general pediatric population.

The clinical presentation is typically mild \[[@CR1]\]. In a recent USA report \[[@CR6]\], fever, cough, and especially shortness of breath are commonly reported among adult patients (71%, 80%, and 43%, respectively) but are less frequently found in children (56%, 54%, and 13%, respectively) \[[@CR8]\]. In our series, 3 of 16 patients were asymptomatic, and fever and/or cough were present in only half of the patients. Remarkably, none of our patients required oxygen therapy. Lymphopenia was an unusual finding as previously reported in pediatric series \[[@CR1]\].

In 2 patients with corticodependent nephrotic syndrome receiving maintenance treatment with immunosuppressors, SARS-CoV-2 infection provoked a relapse, but prednisone treatment response was good in both cases.

Acute kidney injury (AKI) is not commonly reported in COVID-19 disease \[[@CR9]\], but when present, it is associated with a poorer prognosis \[[@CR10]\]. Three children were diagnosed with AKI, with an increase in serum creatinine to 1.5 times baseline (stage 1 AKIN/KDIGO classification). In the 3 cases (2 transplant recipients and an adolescent with ERC stage 2), a prerenal component was present, and in 1 of them, tacrolimus toxicity was also identified. All 3 patients achieved basal GFR in a few days.

Nine of the 16 children received chronic immunosuppression. Although data for immunosuppressed children are scarce, surprisingly, they did not appear to evolve differently from the immunocompetent children. A study performed by the European Society for Gastroenterology \[[@CR11]\] found children with inflammatory bowel disease who presented COVID-19 disease with a mild outpatient course. In a multicentric study of children receiving anticancer chemotherapy, most of the cases have a mild or asymptomatic clinical course \[[@CR12]\]. A recent study performed in Madrid (unpublished work) collecting data from 8 immunocompromised children with COVID-19 had found similar results.

Special consideration must be given to transplant recipients. Data from Hospital Papa Giovanni XXIII of Bergamo \[[@CR13]\] shows that, among approximately 200 pediatric liver transplant recipients controlled in this center, none had developed clinical pulmonary disease, despite 3 having tested positive for SARS-CoV-2. In our own experience, among approximately 420 children with a functioning kidney transplant controlled in pediatric nephrology departments in Spain, only 3 patients have been diagnosed with COVID-19.

There are no general rules about immunosuppression management. Based on experience with other viruses in the transplantation field, antimetabolites are typically reduced or discontinued, but calcineurin inhibitors are maintained if the clinical course is not severe. Evolutions have been favorable, even in cases with any modification that has been done.

Antiviral treatment was prescribed according to general practice advice for the Spanish pediatric population \[[@CR14]\]. One patient initially received lopinavir/ritonavir, but administration had to be stopped due to digestive intolerance; it was replaced with hydroxychloroquine. The other 8 patients were only treated with hydroxychloroquine. We must be careful when recommending a specific antiviral treatment for this group of patients, given that pharmacological interactions are very frequent. It is also important to remember that doses must to be adjusted to CKD degree.

In conclusion, in our experience, children with chronic renal pathologies, even with immunosuppression, and COVID-19 disease show the same evolution as healthy children of the same age. Clinical course is typically mild. Renal acute failure could appear if anorexia limits fluid intake. Drug interaction must be kept in mind. Hospitalization should be considered only when the clinical situation suggests it, and these patients can be managed as outpatients if close monitoring is possible.
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